Case Details
- Citation: [2013] SGHCR 7
- Case Title: AstraZeneca AB (SE) v Sanofi-Aventis Singapore Pte Ltd
- Court: High Court (Registrar)
- Coram: Justin Yeo AR
- Date of Decision: 15 March 2013
- Case Number: Suit No 416 of 2011 (Summons No 471 of 2013)
- Plaintiff/Applicant: AstraZeneca AB (SE)
- Defendant/Respondent: Sanofi-Aventis Singapore Pte Ltd
- Counsel for Plaintiff: Mr Alvin Lim and Mr Sandeep Menon (Rodyk & Davidson LLP)
- Counsel for Defendant: Mr Jason Chan, Mr Melvin Pang and Ms Anna Toh (Amica Law LLC)
- Legal Area: Patents and Inventions – Infringement; Civil Procedure – Pleadings – Further & Better Particulars
- Statutes Referenced: Medicines Act (Cap 176)
- Other Statutory/Regulatory References: Rules of Court (Cap 322, R 5, 2006 Rev Ed); Patents Act (Cap 221, Rev Ed 2005); Medicines (Licensing, Standard Provisions and Fees) Regulations (Cap 176, S 74, 2000 Rev Ed)
- Key Procedural Provisions: O 18 r 12; O 87A r 2
- Related Earlier Decision: AstraZeneca AB (SE) v Sanofi-Aventis Singapore Pte Ltd [2012] SGHC 16
- Judgment Length: 14 pages, 8,542 words
Summary
This High Court (Registrar) decision concerns a procedural application for further and better particulars in a patent-related dispute arising under the Medicines Act’s “patent notice” and regulatory moratorium framework. AstraZeneca, the proprietor of a Singapore patent for pharmaceutical compositions comprising rosuvastatin and a particular class of inorganic multivalent-cation salts, sued Sanofi after Sanofi applied to the Health Sciences Authority (HSA) for product licences for its rosuvastatin film-coated tablets. AstraZeneca sought declarations that Sanofi’s acts in Singapore would infringe the patent claims.
After an earlier strike-out application was dismissed on the basis that the Medicines Act created an independent cause of action requiring only a prospect of infringement, Sanofi sought further and better particulars. The Registrar held that the court’s power to order particulars under O 18 r 12 applies to patent actions, but that patent infringement pleadings also attract the specific requirement in O 87A r 2(2) to serve particulars of infringement showing which claims are alleged to be infringed and giving at least one instance of each type of infringement alleged. The decision focuses on the “office” of particulars of infringement—how much detail a patentee must provide at the pleading stage without being forced into premature claim construction or evidential disclosure.
What Were the Facts of This Case?
AstraZeneca is the proprietor of Singapore Patent No SG 89993, titled “Pharmaceutical Compositions Comprising a HMG COA Reductase Inhibitor”. The patent specification describes pharmaceutical compositions comprising rosuvastatin (as the active ingredient) and an inorganic salt with a multivalent cation. The specification also indicates that the composition is preferably in tablet form. The patent contains 27 claims, and Claim 1 is central to the dispute: it covers a pharmaceutical composition for treating high cholesterol comprising rosuvastatin and an inorganic salt with a multivalent cation, subject to exclusions (the inorganic salt is neither hydrotalcite nor synthetic hydrotalcite, and the counter anion is not a phosphate).
On 1 April 2011, Sanofi applied to the HSA for product licences for its Rosucard Film-coated Tablets in 10mg, 20mg and 40mg dosage forms. Under the Medicines Act regime, when a generic or competing applicant seeks regulatory approval, the patent proprietor can be notified and can initiate proceedings to trigger a regulatory moratorium. On 26 April 2011, AstraZeneca was served with a Notice to Proprietor of Patent pursuant to s 12A(3)(a) of the Medicines Act, informing it that Sanofi had made the HSA applications.
On 10 June 2011, AstraZeneca commenced the action seeking a declaration that Sanofi’s disposal, offer to dispose, use, import and keeping of the Defendant’s Products would infringe all 27 claims if carried out in Singapore. The practical effect of commencing the action was to set in place a 30-month moratorium on the processing of Sanofi’s product licence applications, pursuant to s 12A(6) of the Medicines Act and regulation 5B(4) of the Medicines (Licensing, Standard Provisions and Fees) Regulations.
AstraZeneca later filed an amended Statement of Claim (Amendment No 1) dated 5 July 2011. Sanofi had previously applied to strike out the action, arguing that the amended pleading disclosed no act of infringement and therefore disclosed no reasonable cause of action under the Patents Act. AstraZeneca responded that the action was based on an independent cause of action created by s 12A of the Medicines Act, which did not require an infringement act to have already occurred. That strike-out application was heard in December 2012 and dismissed in AstraZeneca AB (SE) v Sanofi-Aventis Singapore Pte Ltd [2012] SGHC 16. The court held that s 12A contemplates a cause of action independent of a traditional patent infringement action and requires only a prospect of infringement; AstraZeneca’s disbelief of Sanofi’s opinion on non-infringement was sufficient to sustain the action.
Following that, AstraZeneca sought discovery of the “Product Descriptions” of Sanofi’s products, arguing it needed them to understand how Sanofi could be infringing. The court allowed this discovery on 24 August 2012, and Sanofi provided chemical composition information, including amounts and weights of active ingredients and excipients. Despite this, on 14 December 2012 Sanofi requested further and better particulars by letter, contending that AstraZeneca’s pleading did not provide enough detail about the alleged infringement. AstraZeneca refused, taking the position that the requests were really about claim construction rather than particulars of infringement. Sanofi then brought the present application under O 18 r 12 and O 87A r 2.
What Were the Key Legal Issues?
The principal issue was the scope of the patentee’s obligation to provide “further and better particulars” in a patent infringement-related action, particularly where the substantive claim is brought under the Medicines Act’s s 12A framework rather than a conventional infringement action under the Patents Act. The Registrar had to decide whether the procedural rules governing particulars in patent actions apply in the same way to Medicines Act proceedings and, if so, what level of detail is required.
A second issue concerned the “office” of particulars of infringement: how much detail must a patentee provide in the pleadings to inform the defendant of the nature of the case to be met, without forcing the patentee to commit to a definitive claim construction or to disclose evidence prematurely. The court also had to consider whether the requested particulars would improperly require AstraZeneca to plead its construction of the patent claims at too early a stage.
Finally, the Registrar had to apply these principles to the specific requests made by Sanofi, assessing whether AstraZeneca’s existing pleading already sufficiently identified the claims allegedly infringed and the types of infringement relied upon, and whether additional particulars were necessary to avoid surprise or to enable proper preparation for trial.
How Did the Court Analyse the Issues?
The Registrar began by addressing the procedural framework. Both parties proceeded on the basis that the Rules of Court provisions relating to pleadings and particularity in patent actions under the Patents Act apply similarly to actions under the Medicines Act. The Registrar accepted that approach, seeing no reason to depart from it. This meant that the court’s general power to order particulars under O 18 r 12(3) could be invoked to require a party to serve particulars of claims, defences or other matters stated in pleadings, on terms the court considers just.
In explaining the purpose of particulars, the Registrar emphasised that particulars serve to inform the other side of the nature of the case it must meet, prevent trial by ambush, and enable the other side to know what evidence it should prepare. Particulars also promote clarity and precision of the issues and reduce the need for later remedial steps when pleadings are insufficient. These principles are consistent with the general civil procedure rationale for pleadings and particularity.
However, patent infringement pleadings are subject to an additional, specific requirement. Under O 87A r 2(2), the plaintiff must serve with the statement of claim “particulars of the infringement relied on”, showing which claims in the patent specification are alleged to be infringed and giving at least one instance of each type of infringement alleged. The Registrar noted that O 87A r 2(2) does not itself define how extensive those “particulars of the infringement” must be. Therefore, the court turned to case law describing the “office” of particulars of infringement.
The analysis then traced the evolution of the English law approach to particulars of infringement. The Registrar referred to Wenham Co Ltd v Champion Gas Lamp Co Ltd and Todlenhaupt and Co [1891] 8 RPC 22 as a locus classicus for the traditional position. In Wenham, the court held that defendants were not entitled to demand a definite construction of the patent specification at the particulars stage. The object of particulars was to tell the defendants what the plaintiff said the defendants had done in infringement of the patent, not to compel early claim construction. The Registrar treated this as reflecting a balance: enough information to understand the alleged infringement theory, but not so much as to require premature commitment to claim interpretation.
At the same time, the Registrar acknowledged that later cases developed a more nuanced approach. Marsden v Albrecht and Albrecht (1910) 27 RPC 785 illustrates a situation where the particulars were effectively conclusory—substantially alleging infringement of all claims without meaningful differentiation. In such circumstances, the court was prepared to require more detail because the defendants needed to know what they were alleged to have infringed and how. The Registrar’s discussion indicates that the sufficiency of particulars is fact-sensitive and depends on the extent to which the pleading provides a workable framework for the defendant’s preparation.
Although the extract provided is truncated, the Registrar’s method is clear: the court would apply the principles governing the office of particulars to the particular requests before it. This requires distinguishing between (i) particulars that clarify the infringement allegation (for example, identifying which claim elements are said to be met by the defendant’s product and what type of infringement is relied upon), and (ii) requests that effectively seek claim construction arguments or evidential detail that should be dealt with later through claim interpretation and trial evidence.
Importantly, the Registrar also had to consider the context of Medicines Act proceedings. Because s 12A actions are designed to address regulatory applications and the risk of infringement before actual infringement acts occur, the pleading may necessarily be framed in terms of prospective infringement. That context affects how particulars should be assessed: the defendant may have access to product descriptions through discovery, but the patentee’s infringement theory still needs to be pleaded with sufficient clarity to satisfy O 87A r 2(2). The court therefore had to ensure that the defendant was not left guessing about the infringement case, while also preventing the particulars process from becoming a vehicle to force early claim construction.
What Was the Outcome?
The Registrar granted the application for further and better particulars in part, requiring AstraZeneca to provide additional particulars of infringement consistent with O 87A r 2(2) and the general objectives of O 18 r 12. The practical effect was to refine the infringement case at the pleading stage so that Sanofi could understand the nature of AstraZeneca’s allegations and prepare its evidence and arguments accordingly.
At the same time, the decision reflects that the court would not permit particulars to be used to compel AstraZeneca to provide a definitive construction of the patent claims or to disclose matters that properly belong to claim interpretation and trial. The outcome therefore balanced procedural fairness with the need to avoid premature substantive adjudication through pleadings.
Why Does This Case Matter?
This decision is significant for practitioners because it clarifies how Singapore courts approach the level of detail required in patent infringement pleadings, particularly in the distinctive Medicines Act s 12A setting. While the substantive cause of action under s 12A is independent and prospect-based, the procedural obligations for particulars remain important. The case demonstrates that defendants are entitled to meaningful infringement particulars, not merely broad assertions that “all claims” are infringed.
From a litigation strategy perspective, the decision underscores that particulars should be drafted to satisfy both the general civil procedure purposes (notice, clarity, and avoidance of surprise) and the patent-specific requirement in O 87A r 2(2) (identifying the claims alleged to be infringed and giving at least one instance of each type of infringement). Plaintiffs should therefore ensure that their pleadings connect the defendant’s product features (as disclosed through discovery or otherwise) to the patent claim elements, at least at a level sufficient to define the infringement theory.
For defendants, the case provides a framework for seeking further particulars without overreaching. Requests that amount to demanding early claim construction or that seek to litigate the merits through pleadings may be resisted. However, where the pleading is insufficiently particularised—such that the defendant cannot understand the case it must meet—courts are willing to order additional particulars. This makes the decision a useful authority for both sides when calibrating pleading detail and managing the boundary between particulars and substantive claim interpretation.
Legislation Referenced
- Medicines Act (Cap 176, 1985 Rev Ed), in particular s 12A (including s 12A(3)(a) and s 12A(6))
- Medicines (Licensing, Standard Provisions and Fees) Regulations (Cap 176, S 74, 2000 Rev Ed), in particular regulation 5B(4)
- Rules of Court (Cap 322, R 5, 2006 Rev Ed), in particular O 18 r 12 and O 87A r 2
- Patents Act (Cap 221, Rev Ed 2005) (referenced in the procedural history and strike-out context)
Cases Cited
- AstraZeneca AB (SE) v Sanofi-Aventis Singapore Pte Ltd [2012] SGHC 16
- AstraZeneca AB (SE) v Sanofi-Aventis Singapore Pte Ltd [2013] SGHCR 7
- Wenham Co Ltd v Champion Gas Lamp Co Ltd and Todlenhaupt and Co [1891] 8 RPC 22
- Marsden v Albrecht and Albrecht (1910) 27 RPC 785
Source Documents
This article analyses [2013] SGHCR 7 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.